3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Prostatic Neoplasms
2
Urogenital Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Optic Neuritis
1
Myelitis, Transverse
1
Myelitis
1
Hematologic Neoplasms
1
Genital Neoplasms, Male
1
Carcinoma, Non-Small-Cell Lung
1
Brain Neoplasms
1
Interventions
Carboplatin
121
pembrolizumab
119
Pemetrexed
102
Cisplatin
76
Paclitaxel
56
osimertinib
52
Nivolumab
50
Docetaxel
50
durvalumab
47
Specimen Handling
37
Gemcitabine
34
Magnetic Resonance Spectroscopy
33
Radiosurgery
27
Cetuximab
26
130-nm albumin-bound paclitaxel
26
atezolizumab
25
Radiotherapy
20
Ipilimumab
19
Drug Therapy
19
Bevacizumab
19
cemiplimab
17
amivantamab
17
Taxes
16
Ramucirumab
13
alectinib
12
tislelizumab
11
lazertinib
11
Leucovorin
11
Fluorouracil
11
Radiation
10
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Non-Small-Cell Lung
×
Adrenal Cortex Hormones
×
90 days
×
Clear all
NCT06780085
2026-05-26
MK-3475-01H
Merck Sharp & Dohme LLC
Phase 2
Recruiting
96 enrolled